Novavax Inc vs Pinterest Inc — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while Pinterest Inc trades at $21.31 (market cap $11.63B). The key difference: Pinterest Inc is far larger — about 6.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Pinterest Inc for 85 Days on average.
| NVAX | PINS | |
|---|---|---|
Market Cap | $1.82B | $11.63B |
Volume | 6,198,505 | 12,792,940 |
Sector | Health | Media |
52-Week High | $12.56 | $35.24 |
52-Week Low | $6.22 | $15.42 |
Typical Hold Time | 59 Days | 85 Days |
Enterprise Value | $1.39B | $11.55B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Pinterest (PINS) trades at $21.35, up 5.1% today, showing strong momentum after three consecutive earnings beats. The stock maintains a bullish technical outlook with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth accelerated to $4.22 billion in 2025 with improving profitability, though valuation multiples remain elevated with a P/E of 60.4. Recent news highlights the company's visual search ad innovations and international monetization progress.
The outlook remains positive with 54% analyst buy ratings and a $27.93 consensus price target representing 31% upside. Key opportunities include continued international ARPU growth and AI-driven advertising enhancements. Risks include competitive pressure from larger platforms, potential advertising slowdowns, and insider selling activity that may signal caution among company leadership.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →